Quinine has been used since the 1930s to treat idiopathic muscular cramps. However, in 2006, because of efficacy and safety issues, the US Food and Drug Administration cautioned about this off-label use of quinine, citing "665 reports of adverse events with serious outcomes…including 93 deaths." 1 Despite warnings, quinine is still prescribed to individuals with idiopathic muscular cramps. Furthermore, many drinks such as bitter lemon or tonic waters contain quinine, and hence, many may be exposed to quinine daily. This study explored the association between long-term quinine exposure and all-cause mortality.
Methods | This study used data recorded in The Health Improvement Network (THIN), a UK primary care database containing anonymized data on more than 12 million individuals representative of the UK population. 2 The protocol for THIN to obtain and provide anonymous patient data was approved by a national ethics committee in 2002; need for informed consent was waived. Adults who received incident quinine salt (sulfate, bisulfate, dihydrochloride) prescriptions for idiopathic muscular cramps or restless leg syndrome for at least 1 year from January 1990 to December 2014 (last follow-up December 2015) at a mean dosage of 100 mg/d or more were considered to be exposed. This definition was chosen because the period of risk is unknown and most patients stopped quinine within weeks of death. The start date (ie, start of at-risk period) was defined as the first day of the first prescription of quinine. Individuals with muscular cramps or restless leg syndrome, never exposed to quinine or its derivatives, and with at least 1-year follow-up after a randomly selected start date were eligible to be included in the unexposed sample. Three unexposed individuals were selected for every exposed individual. The samples were stratified by sex and age. Group characteristics were compared using the χ 2 test or the Wilcoxon ranksum test. The primary outcome (all-cause mortality) was compared between the exposed and the unexposed populations using Cox proportional hazards models adjusted for sociodemographic data, underlying conditions, and concomitant prescriptions. Post hoc subgroup analyses were conducted by age and amount of exposure (averaged over the exposure period). The proportional hazards assumption for Cox models was checked graphically using the Schoenfeld residuals. Analyses were done using Stata (StataCorp), version 14.0. A 2-sided P value less than .05 denoted statistical significance. a All hazard ratios were statistically significant (all P values <.001, except for adjusted hazard ratios regarding individuals older than 70 years with restless leg syndrome [P = .02]). b All adjusted models were adjusted on age and sex. All the following variables were further considered to be included in the Cox multivariable models: body mass index (<18, 18-24.9, 25-29.9, Ն30; calculated as weight in kilograms divided by height in meters squared), Townsend deprivation score, smoking status, history of cancer, hematological malignancy, diabetes, hypertension, coronary artery disease, congestive heart failure, peripheral ischemic vascular disease, cardiac conduction disorders, cardiac dysrhythmias, amyotrophic lateral sclerosis, multiple sclerosis, or muscular dystrophies, number of prescriptions of diuretics, β-blockers, calcium channel blockers (including diltiazem), oral glucocorticoids, and oral nonsteroidal anti-inflammatory drugs. Some first-order interaction terms (eg, interactions between group and sex, coronary artery disease and congestive heart failure, coronary artery disease and peripheral ischemic vascular disease) were also considered to be included in the models. Variables to be retained in the models were selected using manual stepwise procedures with backward selection. The final models were selected as those that provided the lowest Akaike information criterion and Bayesian information criterion. c Adjusted on age and sex only. 
COMMENT & RESPONSE

Use of the qSOFA Score in the Emergency Department
To the Editor The quick Sequential Organ Failure Assessment (qSOFA) score is much simpler and faster to accomplish than other screening tools and does not require results from laboratory analyses or invasive monitoring. It represents a useful score for the emergency department and ward. The study by Dr Freund and colleagues 1 concluded that "qSOFA resulted in greater prognostic accuracy for in-hospital mortality than did either SIRS [systemic inflammatory response syndrome] or severe sepsis." Unfortunately, these conclusions are based on inconsistent methods, questionable definitions, and a data set with a substantial amount of missing values. Why were 149 patients excluded because of missing data for qSOFA, whereas 260 patients with at least 1 missing component for SOFA were included? This inconsistency could result in lower SOFA scores and an underestimation of disease severity with SOFA. It also gives an important methodical advantage to the qSOFA score.
In addition, severe sepsis was defined as SIRS combined with elevated lactate levels. All the other types of organ dysfunction that were mentioned in the original guidelines by Bone and colleagues 2 and earlier international sepsis definitions 3 (ie, arterial hypotension, encephalopathy, thrombocytopenia, renal dysfunction, hypoxia) were not considered. As a consequence of this arbitrary definition, the presented comparison between qSOFA and severe sepsis is only valid for this subgroup of severe sepsis but not for severe sepsis in general. Despite these limitations, severe sepsis performed as well as qSOFA (positive predictive value 20% for severe sepsis vs 24% for qSOFA; negative predictive value 94% for severe sepsis vs 97% for qSOFA). In addition, the proportion of in-hospital deaths among patients with a qSOFA score of 2 or more points (24%) was similar to that of patients with severe sepsis (20%).
We are aware of the challenges of score calculation in clinical practice. Data are often incomplete because the required laboratory values may not be available for all patients. Against the background of the discussed limitations, however, such a strong conclusion about the superiority of qSOFA over severe sepsis does not seem to be appropriate.
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